Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PPM1B | O75688 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8891623 | 1.00 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4221 | 1.00 | — | — | |
| SCHEMBL237380 | 1.00 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| Hydrochloric Acid SCHEMBL28788727 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL27635791 | 0.95 | MAPT (0.56) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL18417194 | 0.93 | MAPT (0.55) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL13044829 | 0.93 | MAPT (0.55) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL15798012 | 0.91 | MAPT (0.53) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL1297615 | 0.91 | GAA (0.59) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL1286694 | 0.91 | MAPT (0.53) | MAPTALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706627-A2 | LAUNDRY COMPOSITION | Firmenich SA (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-4077626-B1 | LAUNDRY COMPOSITION | FIRMENICH & CIE (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-RE50267-E1 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2025-01-09 | — | — | US | disclosed |
| CN-118530549-A | Yellowing-resistant flame-retardant material for optical cable sheath and preparation method thereof | 富通光纤光缆（深圳）有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4338761-A1 | PERFUMING COMPOSITIONS | Firmenich SA (CH) | 2024-03-20 | — | — | EP | disclosed |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-3884934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID | ARENA PHARM INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3884934-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2280696-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2009018656-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-5614486-A | DIETHYL 1,4-CYCLOHEXANEDICARBOXYLATE | FIRMENICH SA (CH) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | MAPT 3621/4885ALDH1A1 2570/4885PPM1B 2563/4885 |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | MAPT 4750/4885ALDH1A1 3056/4885PPM1B 3217/4885 |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PLOD3 | MAPT 3580/4885ALDH1A1 2366/4885PPM1B 2886/4885 |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | MAPT 3382/4885ALDH1A1 1257/4885PPM1B 545/4885 |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | MAPT 2657/4885ALDH1A1 737/4885PPM1B 2530/4885 |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | MAPT 2657/4885ALDH1A1 737/4885PPM1B 2530/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | MAPT 3062/4885ALDH1A1 704/4885PPM1B 2546/4885 |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | MAPT 3592/4885ALDH1A1 2589/4885PPM1B 2585/4885 |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | MAPT 3621/4885ALDH1A1 2570/4885PPM1B 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.